Ariad Retreats From Europe Via Incyte Deal
Ariad Pharmaceuticals Inc., a company which has been plagued by setbacks for its leading marketed product, Iclusig (ponatinib), has completed the sale of its European business to Incyte Corp. for $140m.
You may also be interested in...
More and larger M&A deals could boost public biopharmaceutical companies, so investors will watch closely to see if Pfizer's $14bn Medivation acquisition kicks off a widespread spending spree. Speculation about who'll be bought next is in full swing.
The biotech has been streamlining its operations through licensing deals and changing its R&D strategy to better reflect its new geographic makeup – moves that could make it attractive to buyers.